UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selective SERCA2a activator as a candidate for chronic heart failure therapy

Journal of translational medicine, 2024-01, Vol.22 (1), p.77-13, Article 77

2024

Volltextzugriff (PDF)

Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan

The pharmacogenomics journal, 2021-06, Vol.21 (3), p.346-358

2021

Volltextzugriff (PDF)

Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition

British journal of pharmacology, 2013-08, Vol.169 (8), p.1849-1861

2013

Volltextzugriff (PDF)

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab

Frontiers in physiology, 2021-04, Vol.12, p.658790

2021

Volltextzugriff (PDF)

Organ Hypertrophic Signaling within Caveolae Membrane Subdomains Triggered by Ouabain and Antagonized by PST 2238

The Journal of biological chemistry, 2004-08, Vol.279 (32), p.33306-33314

2004

Volltextzugriff (PDF)

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies

Science translational medicine, 2010-11, Vol.2 (59), p.59ra86

2010

Volltextzugriff (PDF)

Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury

International journal of molecular sciences, 2016-10, Vol.17 (10), p.1728-1728

2016

Volltextzugriff (PDF)

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies

Science translational medicine, 2010-11, Vol.2 (59), p.59ra87

2010

Volltextzugriff (PDF)

Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake

PloS one, 2014-04, Vol.9 (4), p.e95771-e95771

2014

Volltextzugriff (PDF)

Istaroxime, a Stimulator of Sarcoplasmic Reticulum Calcium Adenosine Triphosphatase Isoform 2a Activity, as a Novel Therapeutic Approach to Heart Failure

The American journal of cardiology, 2007-01, Vol.99 (2), p.S24-S32

2007

Volltextzugriff (PDF)

Left Ventricular Mass, Stroke Volume, and Ouabain-Like Factor in Essential Hypertension

Hypertension (Dallas, Tex. 1979), 1999-09, Vol.34 (3), p.450-456

1999

Volltextzugriff (PDF)

Plasma Ouabain-Like Factor During Acute and Chronic Changes in Sodium Balance in Essential Hypertension

Hypertension (Dallas, Tex. 1979), 2001-08, Vol.38 (2), p.198-203

2001

Volltextzugriff (PDF)

SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy

Cardiovascular research, 2022-03, Vol.118 (4), p.1020-1032

2022

Volltextzugriff (PDF)

Adducin polymorphisms and the treatment of hypertension

Pharmacogenomics, 2007-05, Vol.8 (5), p.465-472

2007

Volltextzugriff (PDF)

Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function

The Journal of pharmacology and experimental therapeutics, 2023-01, Vol.384 (1), p.231-244

2023

Volltextzugriff (PDF)

Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure

Journal of medicinal chemistry, 2022-05, Vol.65 (10), p.7324-7333

2022

Volltextzugriff (PDF)

Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment

Vascular pharmacology, 2024-06, Vol.155, p.107295, Article 107295

2024

Volltextzugriff (PDF)

Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function

Vascular pharmacology, 2022-10, Vol.146, p.107028, Article 107028

2022

Volltextzugriff (PDF)

Abstract P118: Antihypertensive Treatment Guided By Genetics: Pearl-ht, The Randomized Proof-of-concept Trial Comparing Rostafuroxin With Losartan

Hypertension (Dallas, Tex. 1979), 2020-09, Vol.76 (Suppl_1)

2020

Volltextzugriff (PDF)

Early consequences of the phospholamban mutation PLN‐R14del+/− in a transgenic mouse model

Acta Physiologica, 2024-03, Vol.240 (3), p.e14082-n/a

2024

Volltextzugriff (PDF)

Endogenous ouabain in cardiovascular function and disease

Journal of hypertension, 2009, Vol.27 (1), p.9-18

2009

Volltextzugriff (PDF)

Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension

American journal of physiology. Regulatory, integrative and comparative physiology, 2006-03, Vol.290 (3), p.R529-R535

2006

Volltextzugriff (PDF)

A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin

Cardiovascular & hematological agents in medicinal chemistry, 2006-01, Vol.4 (1), p.61-66

2006

Volltextzugriff (PDF)

Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain

The Journal of pharmacology and experimental therapeutics, 2014-11, Vol.351 (2), p.278-287

2014

Volltextzugriff (PDF)

Renal Na,K-ATPase in Genetic Hypertension

Hypertension (Dallas, Tex. 1979), 1996-12, Vol.28 (6), p.1018-1025

1996

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(76)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(51)
Animals
(41)
Humans
(35)
Rats
(28)
Biological And Medical Sciences
(23)
Cardiovascular System & Cardiology
(23)
Medical Sciences
(23)
Male
(21)
Hypertension
(19)
Peripheral Vascular Disease
(18)
Cardiology. Vascular System
(17)
Arterial Hypertension. Arterial Hypotension
(16)
Blood And Lymphatic Vessels
(16)
Hypertension - Metabolism
(14)
Adducin
(13)
Female
(13)
Hypertension - Physiopathology
(12)
Blood Pressure
(11)
Sodium-Potassium-Exchanging Atpase - Metabolism
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective SERCA2a activator as a candidate for chronic heart failure therapy

Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan

Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab

Organ Hypertrophic Signaling within Caveolae Membrane Subdomains Triggered by Ouabain and Antagonized by PST 2238

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies

Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies

Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake

Istaroxime, a Stimulator of Sarcoplasmic Reticulum Calcium Adenosine Triphosphatase Isoform 2a Activity, as a Novel Therapeutic Approach to Heart Failure

Left Ventricular Mass, Stroke Volume, and Ouabain-Like Factor in Essential Hypertension

Plasma Ouabain-Like Factor During Acute and Chronic Changes in Sodium Balance in Essential Hypertension

SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy

Adducin polymorphisms and the treatment of hypertension

Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function

Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure

Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment

Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function

Abstract P118: Antihypertensive Treatment Guided By Genetics: Pearl-ht, The Randomized Proof-of-concept Trial Comparing Rostafuroxin With Losartan

Early consequences of the phospholamban mutation PLN‐R14del+/− in a transgenic mouse model

Endogenous ouabain in cardiovascular function and disease

Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension

A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin

Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain

Renal Na,K-ATPase in Genetic Hypertension

Suchergebnisse filtern